Merrimack Pharmaceuticals (MACK) Earns Daily Media Impact Rating of 0.19

News stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 49.0249286792687 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Separately, Robert W. Baird restated a “hold” rating and set a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th.

Shares of Merrimack Pharmaceuticals stock opened at $9.67 on Thursday. Merrimack Pharmaceuticals has a one year low of $9.54 and a one year high of $39.90. The stock has a market cap of $133.56, a price-to-earnings ratio of 0.27 and a beta of 1.59.

ILLEGAL ACTIVITY NOTICE: “Merrimack Pharmaceuticals (MACK) Earns Daily Media Impact Rating of 0.19” was originally posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://baseballnewssource.com/2018/03/22/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-merrimack-pharmaceuticals-mack-stock-price/1925891.html.

Merrimack Pharmaceuticals Company Profile

Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.